RespireRx Pharmaceuticals (OTCQB:RSPI) Inc announced that its dronabinol obstructive sleep apnea (OSA) program has been featured in a free e-book published in the June 13, 2022, edition of Sleep Review magazine.
The e-book, entitled 'How Close Are We to Drug Therapy for Obstructive Sleep Apnea?' discusses dronabinol as one of four emerging drug treatments for the treatment of OSA. The book can be read here.
“For decades, scientists have been searching for a drug therapy for obstructive sleep apnea,” Sleep Review editor Sree Roy said in a statement. “An oral pharmacologic treatment that keeps airways open during sleep would be a game-changer.”
READ: RespireRx Pharmaceuticals Interim CEO talks AMPAkines in treating GRI disorders at virtual conference
Roy continued, “An oral pharmacologic treatment would represent a shift in the perception of sleep apnea therapy, likely resolving adherence obstacles associated with medical device-based treatments for many patients. It could also lead to increased willingness among people with OSA symptoms to undergo sleep testing.”
To date, RespireRx noted, two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to significantly reduce the symptoms of OSA. If the finances can be raised, RespireRx believes that it can commence a pharmacokinetic study for a recently discovered and to-be-developed formulation followed by a Phase 3 clinical study for the treatment of OSA with the new formulation.
“I wonder how many people who experience excessive daytime sleepiness refuse diagnosis because they are intimidated by currently available sleep apnea treatment options (or at least by their limited knowledge of available treatments),” Roy concluded. “Sleep specialists too would also welcome another treatment option—more therapies mean more opportunities to find a therapy most compatible to every patient.”
RespireRx Pharmaceuticals (OTCQB:RSPI) is a biopharmaceutical company developing innovative and revolutionary treatments for disorders caused by the disruption of neuronal signaling, including obstructive sleep apnea, attention deficit hyperactivity disorder, epilepsy, chronic pain, and spinal cord injury.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter (NYSE:TWTR) @andrew_kessel